NYSE American - Nasdaq Real Time Price USD

Scorpius Holdings, Inc. (SCPX)

0.0777

+0.0009

(+1.17%)

At close: 4:00 PM EDT

0.0855

+0.01

(+10.04%)

After hours: 6:33 PM EDT

Scorpius Holdings Achieves Major Milestone with cGMP Facility Validation for Microbial Manufacturing

Gaining operating efficiency through transition to an internal environmental monitoring teamDURHAM, N.C., May 15, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the successful validation of its microbial facilities, marking a significant milestone in the Company's operations. This validation signifies that Scorpius’ microbial cleanrooms are now official

GlobeNewswire 10 hours ago

SCPX
+1.17%
Scorpius Holdings, Inc. Announces Pricing of Public Offering

DURHAM, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of its underwritten public offering of 60,000,000 common units and/or pre-funded units in lieu thereof. Each common (or pre-funded) unit is being offered at a public offering price of $0.10 per unit (inclusive of the pre-funded warrant exercise price) and consists of one

GlobeNewswire yesterday

SCPX
+1.17%
Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald

Biopharma industry veteran joins Scorpius’ leadership teamDURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the appointment of Shari Udoff-McDonald as VP of Business Development. She brings more than 25 years of experience in biopharma business development and management. Prior to joining Scorpius, Ms. Udoff-McDonald spent 17 years at

GlobeNewswire 8 days ago

SCPX
+1.17%
Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023

DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius” or “the Company”), an integrated contract development and manufacturing organization providing state-of-the-art large molecule contract development and manufacturing organization (“CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2023. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, “We are executing our plan to augment sales and drive r

GlobeNewswire 16 days ago

SCPX
+1.17%
Scorpius Holdings Announces Receipt of Filing Delinquency Notification

Reaffirms commitment to regaining compliance with the NYSE American continued listing standardsDURHAM, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation stating that the Company is not in compliance with NYSE American LLC (“NYSE American” or the “Exchange”) continued listing standards (the “Fi

GlobeNewswire 23 days ago

SCPX
+1.17%
Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University

DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a major university. The program involves process optimization and development of a therapeutic antibody, which Scorpius will manufacture for preclinical studies. The work will be conducted in the Company’s state-of-the-art

GlobeNewswire last month

SCPX
+1.17%
Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium

Provides Access to Growth Funding and Enhanced Access to Federal ProjectsDURHAM, N.C., March 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been accepted into the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a part of the National Biopharmaceutical Manufacturing Partnership. The BioMap-Consortium has a $20 billion funding ceiling, throu

GlobeNewswire 2 months ago

SCPX
+1.17%
Scorpius Holdings, Inc. Announces Closing of Public Offering

DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for gross proceeds of $1,500,000, before deducting underwriting discounts and offering expenses. The Company intends to use the proceeds fr

GlobeNewswire 2 months ago

SCPX
+1.17%
SCPX: Sharply Positive Growth

By John Vandermosten, CFA NYSE:SCPX Scorpius Holdings, Inc. (NYSE:SCPX) provided a first look at 4Q:23 results. It is forecasting revenues of $3.4 to $3.6 million, up sequentially from $723,000 in 3Q:23 as published in a March 7th press release . Since our previous update in January, the company has officially changed its name, promoted the Chief Operating Officer, appointed new senior

Zacks Small Cap Research 2 months ago

SCPX
+1.17%
Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock

DURHAM, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced that it intends to offer to sell shares of its common stock to the public in an underwritten public offering. All of the shares of common stock are to be sold by the Company. ThinkEquity is acting as sole book-running manager for the offering. The Company intends to use the net proce

GlobeNewswire 2 months ago

SCPX
+1.17%
Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023

Estimates Sequential Reduction in the Fourth Quarter of 2023 Operating Loss by Over $3.3 Million or Approximately 30% Compared to the Third Quarter of 2023 Achieves Record Backlog of $9.3 Million DURHAM, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc., (“Scorpius”) (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today reported preliminary, unaudited financial results for the fourth quarter of 2023. Jeff Wolf, CEO of Scorpius, stat

GlobeNewswire 2 months ago

SCPX
+1.17%
NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today

DURHAM, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences / Scorpius Holdings, Inc. (NYSE American: NHWK; SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it had completed its name change from NightHawk Biosciences, Inc. to Scorpius Holdings, Inc., to better reflect the Company’s successful shift into a pure-play, large molecule biomanufacturing CDMO. In connection with the name change, the Company’s ticker will change to “SCPX” ef

GlobeNewswire 3 months ago

SCPX
+1.17%
NHWK

Performance Overview

Return	SCPX	S&P 500
YTD	-82.34%	+11.29%
1-Year	-88.74%	+28.71%
3-Year	-98.69%	+27.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Scorpius Holdings, Inc. (SCPX)

Scorpius Holdings Achieves Major Milestone with cGMP Facility Validation for Microbial Manufacturing

Scorpius Holdings, Inc. Announces Pricing of Public Offering

Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald

Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023

Scorpius Holdings Announces Receipt of Filing Delinquency Notification

Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University

Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium

Scorpius Holdings, Inc. Announces Closing of Public Offering

SCPX: Sharply Positive Growth

Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock

Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023

NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today

Performance Overview